News

Pfizer withdraws Oxbryta from global markets, cites safety concerns

Pfizer has voluntarily withdrawn Oxbryta (voxelotor), a conditionally approved oral therapy for sickle cell disease (SCD), from worldwide markets, saying clinical data shows the treatment’s benefit “no longer outweighs the risk.” Citing an imbalance in vaso-occlusive crises (VOCs) and deaths occurring in patients given Oxbryta in postmarketing…